Vaccines for tumour prevention

Despite tremendous progress in basic and epidemiological research, effective prevention of most types of cancer is still lacking. Vaccine use in cancer therapy remains a promising but difficult prospect. However, new mouse models that recapitulate significant features of human cancer progression show that vaccines can keep precancerous lesions under control and might eventually be the spearhead of effective and reliable ways to prevent cancer.

[1]  A. Amici,et al.  Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.

[2]  Variants Coad-Yourdon Shlaer-Mellor.  Advantages and Disadvantages , 1917, The Hospital.

[3]  Alexander Kamb,et al.  What's wrong with our cancer models? , 2005, Nature Reviews Drug Discovery.

[4]  H. Hsu,et al.  Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. , 2000, JAMA.

[5]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[6]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[7]  S. Cingarlini,et al.  Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.

[8]  B. Stewart,et al.  World Cancer Report , 2003 .

[9]  G. Forni,et al.  Immunological inhibition of carcinogenesis , 2004, Cancer Immunology, Immunotherapy.

[10]  Maureen F. Maughan,et al.  Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis , 2004, Breast Cancer Research.

[11]  G. Klein,et al.  Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. , 1998, Journal of immunology.

[12]  L. White.  Studies on Melanoma , 1959 .

[13]  D. Morton,et al.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. , 1998, The Journal of investigative dermatology.

[14]  E. Jaffee,et al.  Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.

[15]  O. Finn,et al.  Premalignant Lesions as Targets for Cancer Vaccines , 2003, The Journal of experimental medicine.

[16]  Piero Musiani,et al.  Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity , 2005, Clinical Cancer Research.

[17]  J. Berzofsky,et al.  Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice , 2004, Cancer Research.

[18]  J. Xia,et al.  Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells 1 , 2003, The Journal of Immunology.

[19]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[20]  Albert R. Jonsen,et al.  The advent of the ‘unpatients’ , 1996, Nature Medicine.

[21]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[22]  M. Boccadoro,et al.  Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy , 1999 .

[23]  Gardasil — the perfect guard? , 2005, Nature Reviews Cancer.

[24]  P. Lollini,et al.  Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants , 1994 .

[25]  M. Colombo,et al.  IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. , 1998, Cancer research.

[26]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[27]  P. Musiani,et al.  Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice , 2001, Gene Therapy.

[28]  J. Berzofsky,et al.  Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas , 2005, The Journal of Immunology.

[29]  Piero Musiani,et al.  Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.

[30]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[31]  M. Blackman,et al.  Vaccine development: baring the 'dirty little secret' , 2005, Nature Medicine.

[32]  M. Bibby,et al.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. , 2004, European journal of cancer.

[33]  D. Pardoll,et al.  Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. , 1998, Journal of immunology.

[34]  A. Houghton,et al.  Stuck in the MUC on the long and winding road , 1998, Nature Medicine.

[35]  B. Stewart,et al.  Cancer prevention: a global perspective. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Ménard,et al.  Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. , 2005, Cancer research.

[37]  J. Schlom,et al.  Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. , 2002, Cancer research.

[38]  B. Knowles,et al.  Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Piero Musiani,et al.  Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.

[40]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[41]  H. Ikeda,et al.  Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. , 1997, Journal of immunology.

[42]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[43]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[44]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[45]  P. Musiani,et al.  Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent1 , 2004, The Journal of Immunology.

[46]  L. Steinman,et al.  Design of effective immunotherapy for human autoimmunity , 2005, Nature.

[47]  S. Plotkin,et al.  Vaccines: past, present and future , 2005, Nature Medicine.

[48]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[49]  D. Stern,et al.  Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.

[50]  P. Triozzi,et al.  Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.

[51]  J. Wolchok,et al.  Immunity to cancer through immune recognition of altered self: studies with melanoma. , 2003, Advances in cancer research.

[52]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[53]  J. Lustgarten,et al.  The CD8+ T cell repertoire against Her‐2/neu antigens in neu transgenic mice is of low avidity with antitumor activity , 2004, European journal of immunology.

[54]  P. Musiani,et al.  LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.

[55]  J. Cuzick.  Breast Cancer Prevention Trials , 2007 .

[56]  P. Musiani,et al.  Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.

[57]  M. Barbacid,et al.  Evaluation of genetic melanoma vaccines in cdk4‐mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin , 2006, International journal of cancer.

[58]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[59]  Ross Upshur,et al.  Vaccines in the public eye , 2005, Nature Medicine.

[60]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Piero Musiani,et al.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.

[62]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  P. Parren,et al.  Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy , 2004, The Journal of Immunology.

[64]  S. Ostrand-Rosenberg,et al.  Animal models of tumor immunity, immunotherapy and cancer vaccines. , 2004, Current opinion in immunology.

[65]  S. Stevanović.  Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[66]  E. Shevach.  Fatal attraction: tumors beckon regulatory T cells , 2004, Nature Medicine.

[67]  P Signorelli,et al.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. , 1997, Journal of the National Cancer Institute.

[68]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[69]  S. Kaufmann.  Novel vaccination strategies. , 2004 .

[70]  P. Musiani,et al.  Immunological Prevention of a Multigene Cancer Syndrome , 2004, Cancer Research.

[71]  L. Kopelovich,et al.  Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein , 2004, The Journal of experimental medicine.

[72]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[73]  T. Noda,et al.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. , 2004, The Journal of clinical investigation.

[74]  P. Lollini,et al.  Cancer immunoprevention: tracking down persistent tumor antigens. , 2003, Trends in immunology.

[75]  K. Foon,et al.  CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice , 2006, Cancer Immunology, Immunotherapy.

[76]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[77]  Weiyi Peng,et al.  Toll-Like Receptor 8-Mediated Reversal of CD4+ Regulatory T Cell Function , 2005, Science.

[78]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[79]  Jeffrey E. Green,et al.  The promise of genetically engineered mice for cancer prevention studies , 2005, Nature Reviews Cancer.

[80]  J. Timmerman,et al.  Cancer vaccines: pessimism in check. , 2004, Nature medicine.

[81]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[82]  S. Rafii.  Vaccination against tumor neovascularization: Promise and reality. , 2002, Cancer cell.

[83]  Laurence Zitvogel,et al.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.

[84]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[85]  G. Ferrara,et al.  The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. , 2003, Cancer research.

[86]  G. Forni,et al.  Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. , 1993, Cancer research.

[87]  G. Forni,et al.  Immunotherapy and immunoprevention of cancer: where do we stand? , 2005, Expert opinion on biological therapy.

[88]  Piero Musiani,et al.  Immunobiology of her-2/neu transgenic mice. , 2004, Breast disease.

[89]  C. Lang,et al.  Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise. , 2001, American journal of physiology. Endocrinology and metabolism.

[90]  G. Forni,et al.  A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. , 2005, Cancer research.

[91]  P. Musiani,et al.  A Limited Autoimmunity to p185neu Elicited by DNA and Allogeneic Cell Vaccine Hampers the Progression of Preneoplastic Lesions in HER-2/NEU Transgenic Mice , 2005, International journal of immunopathology and pharmacology.

[92]  H. Schreiber,et al.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.

[93]  J. Schlom,et al.  Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice , 2004, Cancer Research.

[94]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[95]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[96]  T. Saruta,et al.  Insulin-like Growth Factor-1 (IGF-1)-derived Peptide Protects against Diabetes in NOD Mice , 2004, Autoimmunity.

[97]  Augusto C. Ochoa,et al.  Mechanisms of Tumor Escape from the Immune Response , 2002 .

[98]  R. Henderson,et al.  HSP110-HER2/neu Chaperone Complex Vaccine Induces Protective Immunity Against Spontaneous Mammary Tumors in HER-2/neu Transgenic Mice 1 , 2003, The Journal of Immunology.

[99]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[100]  Makoto Katsumata,et al.  Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.

[101]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[102]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[103]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[104]  J. Cuzick.  Aromatase inhibitors for breast cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  E. Mihich.  Cellular immunity for cancer chemoimmunotherapy—an overview , 2003, Cancer Immunology, Immunotherapy.

[106]  S. Ménard,et al.  p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma , 2000, International journal of cancer.

[107]  G. Haidinger,et al.  [Epidemiology and prevention of breast cancer]. , 2000, Wiener medizinische Wochenschrift.

[108]  B. Kimler,et al.  Selective estrogen-receptor modulators for primary prevention of breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  L. Old,et al.  Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Lustgarten,et al.  Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. , 2003, Cancer research.

[111]  N. Greenberg,et al.  Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization , 2005, European journal of immunology.

[112]  M. Sporn,et al.  Chemoprevention: an essential approach to controlling cancer , 2002, Nature Reviews Cancer.

[113]  Piero Musiani,et al.  Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. , 2004, The Journal of clinical investigation.

[114]  Rustom Antia,et al.  The role of models in understanding CD8+ T-cell memory , 2005, Nature Reviews Immunology.

[115]  P. Lollini,et al.  New target antigens for cancer immunoprevention. , 2005, Current cancer drug targets.

[116]  P. Musiani,et al.  Immunoprevention of cancer: is the time ripe? , 2000, Cancer research.

[117]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[118]  Piero Musiani,et al.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. , 2005, The American journal of pathology.

[119]  Federico Garrido,et al.  The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.

[120]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[121]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.